Literature DB >> 15950799

CT, RECIST, and malignant pleural mesothelioma.

Anna K Nowak1.   

Abstract

The unique growth pattern of malignant pleural mesothelioma (MPM) presents challenges for clinical investigators assessing tumour response to treatment. Assessment of response is an important surrogate for patient benefit, particularly in phase II clinical trials. Neither the previous WHO criteria nor the more recent RECIST criteria are well suited to tumour measurement in this disease. This paper discusses uni-dimensional measurement of tumour response in pleural mesothelioma, and the development and validation of the modified RECIST criteria for MPM, which attempt to overcome some of the shortcomings of the RECIST criteria in this setting.

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 15950799     DOI： 10.1016/j.lungcan.2005.03.030

Source DB:  PubMed          Journal:  Lung Cancer        ISSN： 0169-5002            Impact factor:   5.705


  11 in total

1.  A practical guide of the Southwest Oncology Group to measure malignant pleural mesothelioma tumors by RECIST and modified RECIST criteria.

Authors:  Anne S Tsao; Linda Garland; Mary Redman; Kemp Kernstine; David Gandara; Edith M Marom
Journal:  J Thorac Oncol       Date:  2011-03       Impact factor: 15.609

Review 2.  Imaging-based tumor treatment response evaluation: review of conventional, new, and emerging concepts.

Authors:  Hee Kang; Ho Yun Lee; Kyung Soo Lee; Jae-Hun Kim
Journal:  Korean J Radiol       Date:  2012-06-18       Impact factor: 3.500

3.  [Guidelines of the European Respiratory Society and the European Society of Thoracic Surgeons for the management of malignant pleural mesothelioma].

Authors:  A Scherpereel; P Astoul; P Baas; T Berghmans; H Clayson; P de Vuyst; H Dienemann; F Galateau-Salle; C Hennequin; G Hillerdal; C Le Pe'choux; L Mutti; J-C Pairon; R Stahel; P van Houtte; J van Meerbeeck; D Waller; W Weder
Journal:  Zhongguo Fei Ai Za Zhi       Date:  2010-10

4.  Discrete-space versus continuous-space lesion boundary and area definitions.

Authors:  William F Sensakovic; Adam Starkey; Rachael Y Roberts; Samuel G Armato
Journal:  Med Phys       Date:  2008-09       Impact factor: 4.071

5.  Assessment of objective responses using volumetric evaluation in advanced thymic malignancies and metastatic non-small cell lung cancer.

Authors:  Jeremy Force; Arun Rajan; Eva Dombi; Seth M Steinberg; Giuseppe Giaccone
Journal:  J Thorac Oncol       Date:  2011-07       Impact factor: 15.609

6.  Optimization of response classification criteria for patients with malignant pleural mesothelioma.

Authors:  Zacariah E Labby; Samuel G Armato; Hedy L Kindler; James J Dignam; Arman Hasani; Anna K Nowak
Journal:  J Thorac Oncol       Date:  2012-11       Impact factor: 15.609

7.  Folylpoly-glutamate synthetase expression is associated with tumor response and outcome from pemetrexed-based chemotherapy in malignant pleural mesothelioma.

Authors:  Daniel C Christoph; Bernadette Reyna Asuncion; Celine Mascaux; Cindy Tran; Xian Lu; Murry W Wynes; Thomas C Gauler; Jeremias Wohlschlaeger; Dirk Theegarten; Volker Neumann; Rodrigo Hepp; Stefan Welter; Georgios Stamatis; Andrea Tannapfel; Martin Schuler; Wilfried E Eberhardt; Fred R Hirsch
Journal:  J Thorac Oncol       Date:  2012-09       Impact factor: 15.609

Review 8.  Malignant pleural mesothelioma.

Authors:  Anne S Tsao; Ignacio Wistuba; Jack A Roth; Hedy Lee Kindler
Journal:  J Clin Oncol       Date:  2009-03-02       Impact factor: 44.544

9.  The South West Area Mesothelioma and Pemetrexed trial: a multicentre prospective observational study evaluating novel markers of chemotherapy response and prognostication.

Authors:  C E Hooper; I D Lyburn; J Searle; M Darby; T Hall; D Hall; A Morley; P White; N M Rahman; E De Winton; A Clive; V Masani; D T Arnold; A Dangoor; S Guglani; P Jankowska; S A Lowndes; J E Harvey; J P Braybrooke; N A Maskell
Journal:  Br J Cancer       Date:  2015-03-31       Impact factor: 7.640

Review 10.  Malignant mesothelioma.

Authors:  Alastair J Moore; Robert J Parker; John Wiggins
Journal:  Orphanet J Rare Dis       Date:  2008-12-19       Impact factor: 4.123
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.